Advertisement

Topics

Asterias Biotherapeutics, Inc. Company Profile

10:18 EDT 21st June 2018 | BioPortfolio

Asterias Biotherapeutics is a subsidiary of BioTime, Inc., whose mission is to acquire and develop best in class cell therapy product candidates. Our first acquisition was the stem cell assets of Geron Corporation, which was completed on October 1, 2013. That acquisition includes Geron’s entire cell therapy intellectual property portfolio, existing contracts and license agreements related to their stem cell programs, INDs for OPC1 and VAC1 cell therapies, master cell banks of hESCs and therapeutic cells manufactured under cGMP, research cell banks, customized reagents and equipment, and banks of cGMP-manufactured OPC1 drug product used in Geron’s Phase 1 trial in spinal cord injury, the world’s first human clinical trial of hESC-derived cells.


News Articles [202 Associated News Articles listed on BioPortfolio]

Cancer Research UK and Asterias Biotech initiate immunotherapy trial

Cancer Research UK has initiated a Phase I clinical trial in alliance with US-based Asterias Biotherapeutics to evaluate immunotherapy vaccine...Read More... The post Cancer Research UK and Asterias B...

Cancer Research, Asterias partner on lung cancer vaccine study

Cancer Research UK and Asterias Biotherapeutics agreed to work together to evaluate the AST-VAC2 vaccine in an early-stage st -More- 

CR UK tests Asterias’ novel lung cancer immunotherapy jab

Cancer Research UK has begun testing a novel immunotherapy vaccine for lung cancer in Phase I trials, under a collaboration agreement with Asterias Biotherapeutics.

Asterias enrols and doses first subject in Phase l trial of AST-VAC2

Asterias Biotherapeutics has enrolled and dosed the first subject in a Phase l clinical trial of AST-VAC2 for the treatment...Read More... The post Asterias enrols and doses first subject in Phase l t...

Cancer Research UK and Asterias Biotech initiate trial for immunotherapy vaccine

Cancer Research UK has initiated a Phase I clinical trial in alliance with US-based Asterias Biotherapeutics to evaluate immunotherapy vaccine...Read More... The post Cancer Research UK and Asterias B...

Asterias Biotherapeutics Reports Milestone Targets for 2018

FREMONT, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company pioneering the field of regenerative medicine, today provided its 20...

Asterias Biotherapeutics' (AST) CEO Mike Mulroy on Q1 2018 Results - Earnings Call Transcript

Asterias Biotherapeutics Reports First Quarter Financial Results and Recent Development Progress

-  AST-VAC2 Immunotherapy Program Prepares to Enter Clinic in Second Quarter of 2018 – - Conference Call and Webcast Today, May 9, at 5:00 p.m. ET – FREMONT, Calif., May 09, 2018 (GLOBE NEW...

Drugs and Medications [14 Associated Drugs and Medications listed on BioPortfolio]

Plasmanate [TALECRIS BIOTHERAPEUTICS, INC.]

Plasma Protein Fraction (Human) 5%, USPPlasmanate®

Gamastan s/d [TALECRIS BIOTHERAPEUTICS, INC.]

Immune Globulin (Human)GamaSTAN™ S/DSolvent/Detergent Treated

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 5%, USPPlasbumin ®-5

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 5%, USPPlasbumin ®-5

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 20%, USPPlasbumin®-20

PubMed Articles [21 Associated PubMed Articles listed on BioPortfolio]

Toward best practices in data processing and analysis for intact biotherapeutics by MS in quantitative bioanalysis.

Typically, quantitation of biotherapeutics from biological matrices by LC-MS is based on a surrogate peptide approach to determine molecule concentration. Recent efforts have focused on quantitation o...

Integrated BioTherapeutics.

Discriminating Eaters: Sea Stars Asterias rubens L. Feed Preferably on Mytilus trossulus Gould in Mixed Stocks of Mytilus trossulus and Mytilus edulis L.

Sea stars Asterias rubens are important natural enemies of the blue mussel Mytilus in the North Atlantic. We asked whether these predators distinguish between the cryptic species M. edulis and M. tros...

Glycosimilarity assessment of biotherapeutics 1: Quantitative comparison of the N-glycosylation of the innovator and a biosimilar version of etanercept.

The carbohydrate moieties on the polypeptide chains in most glycoprotein based biotherapeutics and their biosimilars play essential roles in such major mechanisms of actions as antibody-dependent cell...

Targeting Receptor-Type Protein Tyrosine Phosphatases with Biotherapeutics: Is Outside-in Better than Inside-Out?

Protein tyrosine phosphatases (PTPs), of the receptor and non-receptor classes, are key signaling molecules that play critical roles in cellular regulation underlying diverse physiological events. Abe...

Clinical Trials [5 Associated Clinical Trials listed on BioPortfolio]

ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS)

Investigation of the efficacy and safety of triflusal in comparison with aspirin in patients with stable coronary artery disease (CAD) and in those with a history of an acute non-cardioemb...

Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

The purpose of this study is to: - evaluate the safety profile of a single intravenous administration of AIGIV (containing either 3.5 mg/kg, 7.0 mg/kg or 14.0 mg/kg anti-PA IgG) a...

A Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects With Genetically Confirmed Mitochondrial Disease Previously Treated in the Stealth BioTherapeutics SPIMM-201 Study

This is a Phase 2, randomized, double-blind, placebo-controlled crossover study which will enroll up to 36 subjects (anticipated) with genetically confirmed mitochondrial disease who have ...

The Effect of OASIS Ultra on Critical Sized Wound Healing

The aim of this study is to evaluate the speed and quality with which OASIS® Ultra (Healthpoint Biotherapeutics; Fort Worth, Texas) increases wound healing in the critical sized defect. ...

Personalized Immunotherapeutics for Antibiotic-resistant Infection

M. A. suffers from hypogammaglobulinemia that has been complicated by refractory Mycoplasma hominis septic arthritis. He has been receiving the antibiotic valnemulin under Emergency Invest...

Companies [97 Associated Companies listed on BioPortfolio]

BioTime, Inc. and Asterias Biotherapeutics, Inc.

Asterias Biotherapeutics, Inc. is a leading biotechnology company in the emerging field of regenerative medicine. The company’s proprietary, industry leading platforms are ba...

Asterias Biotherapeutics, Inc.

Asterias Biotherapeutics is a subsidiary of BioTime, Inc., whose mission is to acquire and develop best in class cell therapy product candidates. Our first acquisition was the ste...

Axial Biotherapeutics

Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and the central nervous system to develop a new class of biotherapeutics ...

Napro Biotherapeutics Incorporated

NaPro BioTherapeutics, Inc. is a natural product pharmaceutical company focused primarily on the development, manufacture and commercializa tion of paclitaxel, a naturally-occurring anti-cancer agent ...

Sephos Biotherapeutics

Sephos Biotherapeutics is a privately owned company focused on designing drugs for the treatment of cancer stem cells where the structure and biological activity of the drugs have...

More Information about "Asterias Biotherapeutics, Inc." on BioPortfolio

We have published hundreds of Asterias Biotherapeutics, Inc. news stories on BioPortfolio along with dozens of Asterias Biotherapeutics, Inc. Clinical Trials and PubMed Articles about Asterias Biotherapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Asterias Biotherapeutics, Inc. Companies in our database. You can also find out about relevant Asterias Biotherapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...


Corporate Database Quicklinks



Searches Linking to this Company Record